Elevidys Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The elevidys market research report is one of a series of new reports that provides elevidys market statistics, including the elevidys industry's global market size, regional shares, competitors with an elevidys market share, detailed elevidys market segments, market trends and opportunities, and any further data you may need to thrive in the elevidys industry. This elevidys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing investments in the research and development of novel therapies, rising healthcare infrastructure, expanded food and drug administration approvals, high demand from both ambulatory and non-ambulatory duchenne muscular dystrophy patients, and increasing access and reimbursement rates. Major trends in the forecast period include new upcoming therapeutic strategies, including genetic therapies, cell therapy, significant increases in the discovery and development of pharmaceutical drugs, the development of mutation-specific therapies, frequent launches in exon skipping technology, and advancements in genetic research.

The increasing prevalence of Duchenne muscular dystrophy (DMD) is expected to drive the growth of the elevidys market. Duchenne muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene, which results in the absence of dystrophin, a key muscle protein. This leads to progressive muscle weakness and degeneration. The growing burden of DMD is largely attributed to heightened awareness and enhanced diagnostic capabilities, which have enabled earlier and more frequent identification of the condition. Elevidys is used to treat DMD by delivering a micro-dystrophin gene to muscle cells, partially restoring the function of dystrophin. For example, the Murdoch Children’s Research Institute in December 2023 reported that approximately 1,000 people in Australia are affected by Duchenne muscular dystrophy. As the prevalence of DMD rises, the elevidys market is expected to expand accordingly.

A key trend in the elevidys market is the focus on developing innovative treatments, such as gene therapy, to improve early diagnosis and create personalized treatment options for DMD patients. Gene therapy aims to address the genetic cause of DMD by delivering a functional dystrophin gene or its micro-dystrophin variant into muscle cells. In June 2023, Sarepta Therapeutics Inc. announced that the U.S. Food and Drug Administration had approved Elevidys (delandistrogene moxeparvovec-rokl), the first gene therapy for DMD. This approval was granted for ambulatory pediatric patients aged 4 to 5 years with a confirmed DMD gene mutation.

In January 2023, Sarepta Therapeutics entered into a partnership with Catalent to accelerate the development and manufacturing of gene therapies for DMD. The partnership focuses on the production of delandistrogene moxeparvovec (SRP-9001), Sarepta’s gene therapy candidate for DMD. The therapy aims to treat DMD by delivering a gene that creates a shortened version of dystrophin in muscle cells. Catalent Inc. is a leading provider of advanced drug delivery technologies and development solutions.

The key company operating in the elevidys market is Sarepta Therapeutics Inc.

North America was the largest region in the elevidys market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elevidys report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the elevidys market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Elevidys is a prescription gene therapy developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). It targets the root cause of the disease by delivering a shortened but functional version of the dystrophin gene, known as micro-dystrophin, to improve muscle strength and function.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indication for elevidys is Duchenne muscular dystrophy (DMD), although it may be used for other related conditions. DMD is a genetic disorder characterized by the progressive weakening and loss of muscle tissue due to the absence of dystrophin, an essential muscle protein. Elevidys works by introducing a gene that produces micro-dystrophin, a smaller form of dystrophin, to help protect muscle cells and slow the disease's progression. It is distributed through various channels, including specialty pharmacies, hospitals, and clinics, and is used by research institutions and homecare settings.

The elevidys market consists of sales of elevidys suspension. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.